ReviewFrontiers in pharmacology2026
Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the management of type 2 diabetes (T2D) and obesity, with injectable agents demonstrating significant cardiovascular (CV) risk reduction in pivotal trials including LEADER, SELECT, and SUMMIT. However, the reliance on injectable peptide formulations has constrained global accessibility and long-term adherence. The recent emergence of orally bioavailable, nonpeptide, small-molecule GLP-1 RAs-exemplified by orforglipron (Foundayo), danuglipron, and other investigational candidates-marks a paradigm shift in incretin-based therapy. Unlike oral semaglutide, which delivers a peptide via sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC)-mediated absorption with stringent dosing requirements, small-molecule GLP-1 RAs evade enzymatic degradation and facilitate once-daily oral dosing without fasting restrictions or cold-chain logistics. This review synthesizes the pharmacology, Phase 3 clinical evidence (including the ACHIEVE and ATTAIN programs), comparative efficacy against injectable GLP-1 RAs and SGLT2 inhibitors, safety data from over 11,000 patients, and the evolving regulatory landscape-including FDA approval of orforglipron (Foundayo) for chronic weight management in April 2026. We explore positioning within the cardiometabolic treatment algorithm, emphasize limits of indirect comparisons, identify the unresolved cardiovascular outcomes question linked to biased partial agonism, and discuss implications for global access.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.